The FDA's priority review for Opdivo with AVD targets first-line treatment for stage 3 or 4 cHL in patients aged 12 and older. The phase 3 SWOG S1826 study supports the review, focusing on progression ...
CM24 combined with Opdivo and chemotherapy showed significant survival benefits in pancreatic cancer patients with CEACAM1 biomarkers. The study reported up to a 90% reduction in risk of death in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback